RecallClass 4 · Caution in use

Class 4 Medicines Defect Notification: Sandoz Limited, Co-Amoxiclav powder for oral suspension 250/62.5 mg/5mL, EL(26)A/46

Issued 5 Nov 2026 · EL(26)A/46 · Sandoz Limited

Read and act on the official notice on GOV.UK

Print a defect notification check sheet One A4 sheet to work through the shelves and keep as your record.

Class 4 defect notification — Caution in use. The MHRA uses Class 4 when: Usually minor defects in packaging or other printed materials.
What all four recall classes mean
ClassActionThe MHRA's definition
Class 1Immediate actionThe defect presents a risk of death or disability.
Class 2Action within 48 hoursThe defect may cause mistreatment or harm to the patient, but it is not life-threatening or serious.
Class 3Action within 5 daysThe defect is unlikely to cause harm to the patient.
Class 4 this noticeCaution in useUsually minor defects in packaging or other printed materials.

A Class 1 recall usually comes with a National Patient Safety Alert. Source: MHRA, safety communications.

In plain English, for the pharmacy team

Why is this relevant to community pharmacy

This notice is about Co-amoxiclav powder for oral suspension, an antibiotic. The problem is an error in the dosing table in the Summary of Product Characteristics (SmPC), which could lead to about twice the intended dose if it is used for weight-based dosing. It matters to pharmacists and dispensers because the product may be supplied or asked about in the pharmacy, and all batches are affected.

What to tell patients

Use your professional judgement for each patient.

  • Keep taking this medicine as prescribed.
  • If you think you have taken, or given, a higher dose and you have side effects such as diarrhoea, nausea, vomiting or stomach pain, seek immediate medical advice.
  • If you are unsure or have questions, ask your pharmacy or other healthcare professionals involved in your treatment.
  • If you have any adverse reactions, seek medical attention and report them via the Medicines and Healthcare products Regulatory Agency (MHRA) Yellow Card scheme.

What needs to be done

  • Pharmacists: do not use the Sandoz Summary of Product Characteristics (SmPC) dosing table for weight-adjusted dosing of this medicine.
  • Use the corrected dosing information from Annex 1 instead.
  • Be aware that all batches are currently impacted, but the notice says the quality of the powder for oral suspension is not affected.
  • If you are asked about side effects or possible overdose, the notice says suspected adverse reactions should be reported via the MHRA Yellow Card scheme.
  • Read and act on the official GOV.UK notice.

Pharmshark summary, checked and approved by Chris Dotchin on 6 Nov 2026. It is not the official notice: always read and act on the GOV.UK notice.

How this summary was written

An AI tool drafted it from the MHRA's own notice and nothing else. A second check compared every line with the notice. Pharmshark's clinical lead then read it against the notice, edited it where needed and approved it. If the MHRA changes the notice, this summary is taken down until it has been checked again.

The MHRA's summary

Sandoz Limited have informed the MHRA of errors in the dosing table in the Summary of Product Characteristics (SmPC) for Co-amoxiclav 250/62.5 mg/5 ml Powder for Oral Suspension.

Affected batches

Use the GOV.UK notice for the batch numbers. Pharmshark could not list them safely from this notice (for example, they are in a PDF annex, or the table is laid out differently), so none are shown here.

What the notice says about its batches:

Co-Amoxiclav powder for oral suspension 250/62.5 mg/5mL: All batches are currently impacted.

Open the official GOV.UK notice

MHRA's audience tags: All specialties

Pharmshark is not an official alerting route. Make sure your pharmacy receives alerts directly from the MHRA and through your organisation, and always act on the official GOV.UK notice.

Source: the MHRA on GOV.UK. Contains public sector information licensed under the Open Government Licence v3.0. Pharmshark is not affiliated with or endorsed by the MHRA.